4 MICROBIOME R&D BUSINESS COLLABORATION CONGRESS · Yakult Danone India ... • Feed additives to target disease ... • Examining the probiotic market in the Asia-Pacific region

5 - 6 M A R C H 2 0 1 8SINGAPORE, ASIA

4TH MICROBIOME R&D & BUSINESS COLLABORATION CONGRESS

3RD PROBIOTICS CONGRESS: ASIA

www.global-engage .com

Platinum Sponsor 2018

Silver Sponsors 2018

WARM WELCOME

Global Engage is pleased to announce, as part of their worldwide microbiome series, the 4th Microbiome R&D and Business Collaboration Congress and co-located 3rd Probiotics Congress which will be held on March 5-6, 2018 at Hotel Fort Canning, Singapore. The congress which attracted over 180 attendees in 2017, will bring together industry and academic delegates to discuss the latest microbiome research, the development of partnerships and commercial collaborations in this area and the expected growth of product pipelines.

Understanding the human microbiome is one of the most popular focuses of scientific research today. New projects and initiatives are encouraging collaborations and partnerships between industry and academia focused on enabling detailed characterisation of the human microbiota and also to explore the roles that microbes play in both health and disease states.

Attracting over 200 delegates, the co-located meetings will promote comprehensive understanding and reciprocal benefits of the latest scientific and business developments in microbiome and probiotics. The 2-day interactive meeting will highlight cutting edge research and business case studies through expert presentations, and panel discussions exploring key issues in the subject area, an exhibition filled with over 25 solution providers showcasing their products and solutions, as well as networking breaks to promote interactions and business reach with fellow peers.

Having a diverged group of professionals interested in microbiome and probiotics, both scientific and industry talks will take place at this event. Topic areas to be addressed include microbiome in health and disease, skin microbiome, probiotics and brain health amongst others as well as the regulatory issues associated with these areas of research. It is hoped that the meetings will further develop the microbiome and probiotics research, as well as foster more collaborations and commercialisation of the areas in Asia.

ENDANG S. RAHAYUProfessor, Faculty of Agriculture

Technology, Gadjah Mada University, Chairman of Indonesian

Society for Lactic Acid Bacteria (ISLAB), Indonesia

MARK MORRISONProfessor, Chemistry and

Biomolecular Science Chair and Group Leader, Metagenomics

University of Queensland Diamantina Institute, Australia

LEE YUAN KUNAssociate Professor, Department of Microbiology and Immunology National University of Singapore

NEERJA HAJELAGeneral Manager, Science and

Regulatory Affairs, Yakult Danone India

EXPERT SPEAKERS Include:

4TH MICROBIOME R&D AND BUSINESS COLLABORATION CONGRESS / 3RD PROBIOTICS CONGRESS ASIA 2018

CONFERENCE SYNOPSIS

GUT MICROBIOTA IN HEALTH AND DISEASE

• Updates on the Asian gut microbiome project• Novel models for studying gut-microbe interactions• Connections to IBD, IBS and diarrheal diseases• Gut microbiota transplantation• Innate immune system and host-pathogen Interaction• Associations of obesity and metabolic disease• The virome and the role in health and disease• Mechanisms of regulation of microbial virulence in the gut• Role of synthetic biology• Gut-brain interactions – depression, anxiety and autism?• Development of bacteriophage therapeutics• Sequencing and bioinformatics of the human microbiome

• Diversity of skin communities• Interactions between host genotype and microbial abundances• Skin and scalp microbiomes• Case studies and therapeutic potential in acne, eczema, atopic

dermatitis, and microbiomes of chronic and acute wounds• Oral cancer associated microbiome

• Dietary modulation of the human gut microbiome• Gut microbiota in varying nutritional states• Role of the microbiome in food allergy• Role of short-chain fatty acids• Milk-oriented microbiota

• Developing business relationships between academia & pharma• Collaborations/partnerships – the global scope of microbiome

research/structuring successful collaborations• Bringing live microbial products to market – IP, regulation, GMP• Pharmaceutical involvement and therapeutic development• Probiotic strain identification, designation and safety

SKIN, ORAL, LUNG AND VAGINAL MICROBIOTA

MICROBIOTA, DIET, AND PREBIOTICS

COMMERCIALISATION OF MICROBIOME & PROBIOTICS

• Gut-pathogen interactions• Role of probiotics in IBS management• Antibiotic exposure & multidrug resistance• Role of probiotics as anti-diarrhoeal agents• Efficacy and effectiveness of different strains• Biocontrol of gut pathogens with probiotics• Probiotics and the gut-brain axis

PROBIOTICS AND DIGESTIVE HEALTH

• Milk-oriented microbiota• Lactobacilli and bifidobacteria in pediatric illness• Atopic eczema• Probiotic and trial safety in infant populations

PROBIOTICS IN PEDIATRICS

• Reducing the recurrence of urogenital infections in women• Probiotics in bacterial vaginosis• Vaginal microbiome

PROBIOTICS IN WOMEN’S HEALTH

• Nutraceutical and pharmaceutical importance• Dietary intervention & immune response to prebiotics• Role of prebiotics in obesity and type 2 diabetes• Cardiovascular disease and colon cancer risk reduction

FUNCTIONAL FOODS

• Probiotics in animal health• Probiotics in aquaculture• Feed additives to target disease• Antibacterial resistance• Companion and production animals

ANIMAL & AQUACULTURE PROBIOTICS

• Examining the probiotic market in the Asia-Pacific region• Strain identification, designation and safety• Bringing live bacterial products to market• Stable probiotic product storage• IP, regulation and GMP perspective• Clinical trials and health claim substantiation

REGULATION AND PRODUCT DEVELOPMENT

EVENT SPONSORS


Platinum Sponsor 2018

Other Sponsors & Exhibitors 2018

Supporting Partners 2018

Singapore Society of Microbiology and Biotechnology

College of Clinician Scientists

Media Partners 2018

Silver Sponsors 2018

CONFIRMED SPEAKERS

MARK MORRISONChair and Professor, Microbial Biology and Metagonics, University of Queensland Diamantina Institute, Australia

MIKE TAYLORAssociate Professor, Biology Sciences, Faculty of Science, University of Auckland, New Zealand

GAN YUNN HWENAssociate Professor, Department of Biochemistry, National University of Singapore (NUS), Singapore

JUN KUNISAWAHead, Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan

THOMAS DAWSONSenior Principal Investigator, Institute of Medical Biology, A*STAR, Singapore

HIROSHI OHNOGroup Director, Laboratory for Intestinal Ecosystem, RIKEN Centre for Integrative Medical Sciences (IMS), Japan

MARIE DRAGOFounder, Galinee, UK

JIAN-YONG WUAssociate Professor, Department of Applied Biology, Hong Kong Polytechnic University, Hong Kong

LEE YUAN KUN Associate Professor, Department of Microbiology and Immunology, National University of Singapore

LIU JIQUANPrincipal Scientist, Procter and Gamble, Singapore

SENIOR REPRESENTATIVEL'Oreal

PHIL HANSBROProfessor, Professor, NHMRC Fellow and Brawn Fellow, School of Biomedical Sciences and Pharmacy, Newcastle University, Australia

ERIC HUANGProfessor, Department of Life Sciences, National Taiwan University, Taiwan

JASNA RAKONJACAssociate Professor, Institute of Fundamental Sciences, Massey University, New Zealand

NIRANJAN NAGARAJANSenior Group Leader and Associate Director, Computational and Systems Biology, Genome Institute of Singapore (GIS), Singapore

DAVID KYLEChairman and CSO, Evolve Biosystems, USA

TODD KRUEGERPresident and CEO, AOBiome Therapeutics, USA

YOSHIHISA YAMASHITA Professor and Chairperson, Section of Preventive and Public Health Dentistry, Kyushu University, Japan

WON WOO CHOIExecutive Advisor, Genome and Company, Korea

CHARLOTTE TROISEAPAC Scientific Manager, Lesaffre Human Care, Singapore

CAROLINE MONTELIUSAssociate Scientist, Probi AB, Sweden

CLAUS CHRISTOPHERSENSenior Research Fellow, Human Microbiome Collaboration Centre, Curtin University and Edith Cowan University, Australia

PATRICK LEEAssociate Professor, School of Energy and Environment, City University of Hong Kong, Hong Kong

NICK N. GORGANICEO, OzStar Theraupetics, Australia

ANINDYA DASGUPTAWorkstream Leader - GenesisProgram, Unilever R&D, India

JOHN COMMONPrincipal Investigator, Institute of Medical Biology, A*STAR, Singapore

G. BALAKRISH NAIRAg Regional Advisor, Research Policy Cooperation Unit, Communicable Disease Department, World Health Organisation (WHO), India

JANNEKE VAN DE WIJGERTProfessor of Infection and Global Health, Julius Center for Health Sciences and Primary

Care, University Medical Center Utrecht, the Netherlands, Institute of Infection and Global Health, University of Liverpool, UK

TAKASHI OHDANDirector of R&D, Genesis Healthcare Co., Japan

MAMIKO ISAJISenior Scientist, Genesis Healthcare Co., Japan

DEV MITTARLead Scientist, ATCC, USA

HSIN-CHIH LAIDirector, Microbiota Research Center and Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Taiwan


MICROBIOME

NEERJA HAJELA General Manager, Science and Regulatory Affairs, Yakult Danone India

LIONEL BRETON Scientific Director Advanced Research, L’Oreal R&I , Biotherm Advisor, France

SOMYING TUMWASORNAssociate Professor and Head Division of Bacteriology, Faculty of Medicine, Chulalongkorn University, Thailand

LIU SHAO QUANAssociate Professor, Food Science and Technology Programme, Dept. of Chemistry, National University of Singapore (NUS), Singapore

GORDON HOWARTH Professor of Gastrointestinal Physiology, School of Animal and Veterinary Sciences, University of Adelaide, Australia

JOY CHONG Principle Clinical Pharmacist, Watson’s Personal Care Stores, Singapore

ENDANG S. RAHAYUProfessor, Faculty of Agriculture Technology, Gadjah Mada University, Indonesia

SORNTHEP TUMWASORNProfessor, Department of Animal Science, Kasetsart University, Thailand

JI GEUN EOGProfessor, Department of Food and Nutrition, Research Institute of Human Ecology, Seoul National University, Korea

LIONG MIN TZEProfessor, Bioprocessing Technology, Universiti Sains Malaysia, Malaysia

HAZREEN ABDUL MAJIDAssociate Professor, Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Malaysia

ANDERS CERVINProfessor, University of Queensland Centre for Clinical Research, Australia, Royal Brisbane & Women’s Hospital

LIM YIN SZEAssistant Professor and Course Coordinator (Nutrition), School of Biosciences, Faculty of Science, Nottingham University, Malaysia

SEBNEM HARSAProfessor, Department of Food Engineering, Izmir Institute of Technology, Turkey

PRANAB KALITAGlobal Medical Director, GSK Consumer Health, Singapore

SAMANTHA COULSONAdjunct Assoc. Prof, The University of the Sunshine Coast, Australia

CONFIRMED SPEAKERS PROBIOTICS

CONGRESS SCHEDULE DAY 1 MONDAY 5TH MARCH 2018

09:00-09:30

KEYNOTE ADDRESS:MARK MORRISONChair and Professor, Microbial Biology and Metagonics, University of Queensland Diamantina Institute, AustraliaMicrobial Biology and the Small Intestine: The Forgotten Microbiome?Recent technological advances have afforded the opportunity to differentiate

how changes in the microbiota at different body sites may contribute to the onset of chronic, non-communicable diseases. To date, the overwhelming amount of knowledge has been generated using stool samples, with much less interrogation and understanding of mucosa-associated microbial communities; and even less focus on the upper gastrointestinal tract. Indeed, there has been a relative paucity of effort to better characterize and understand the structure-function relationships of the microbiota resident in the upper small intestine, and perhaps, can be considered the forgotten gut microbiome. Innovations in sample collection, microbiota analysis and integration of the data with other clinical measures are all required if the promise and opportunities attributed to “microbiome research” are to be translated into medicine. Here, I will present an overview of the emerging knowledge of the duodenal microbiota, which we contend is dynamic in diversity and size, but resident and site-specific, rather than transient and opportunistic. I will also outline the Australian Gastrointestinal Alliance (AGIRA) and the “Brisbane approach” to building a conceptual framework of the role of the microbiota in the clinical manifestation of functional dyspepsia (FD) and related syndromes. The AGIRA network brings together the multidisciplinary expertise needed to integrate microbiome, immune and dietetic information with other clinical and psychometric assessments of patients with functional gastrointestinal disorders, and by doing so, provides new opportunities to improve the diagnosis and treatment of these patients in a more personalized and precise way.

08:00-08:50

08:55-09:00Global Engage Welcome Address and Morning Chair’s Opening Remarks:Phil Hansbro, Professor, NHMRC Fellow and Brawn Fellow, School of Biomedical Sciences and Pharmacy, Newcastle University, Australia

MICROBIOME PROBIOTICS


09:00-09:30

KEYNOTE ADDRESS:NEERJA HAJELAGeneral Manager, Science and Regulatory Affairs, Yakult Danone IndiaProbiotics in Neonatal Sepsis and Diarrhoea – India StudiesIn the current era of Sustainable Development Goals (SDGs) reducing neonatal and under- five mortality remains a priority. In 2015 diarrhoea caused more than

1.3 million deaths globally in children under five years while Neonatal sepsis in early infancy results in one million deaths annually. The burden is greatest in low and middle-income countries. The significant role of probiotics in intestinal development, immune function and protection against intestinal and enteric infections has been highlighted recently. Although most of these studies have been conducted in high income countries, two very large community based studies were conducted in India to elucidate the role of probiotic and synbiotic preparations in reducing the risk of these infectious diseases. The findings of the studies were encouraging and lend support to the value of this intervention. It is suggested that more research could be the answer for validating the use of alternate interventions in reducing infectious disease burden in the developing part of the world. However, the choice of the probiotic will be important and the results cannot be generalised to all settings and population.

Registration & Refreshments

08:55-09:00Global Engage Welcome Address and Morning Chair’s Opening Remarks:

09:30-10:00

09:00-09:30

LIU SHAO QUANAssociate Professor, Food Science and Technology Programme, Department of Chemistry, National University of Singapore (NUS), SingaporeEnhancing Probiotics Stability in Food Matrices – Interactions between Yeast and ProbioticsProbiotics as beneficial microbes are increasingly popular with consumers. One of

the challenges faced by the food and nutrition industry is how to ensure delivery of sufficient dosage of viable probiotics to consumers so as to meet the minimum therapeutic amount of live probiotics recommended by the International Scientific Association for Prebiotics and Probiotics. Probiotics, as currently defined by WHO, are live microorganisms and thus, are not stable during storage especially in high moisture and acidic food matrices under non-refrigerated conditions. There are a number of approaches to maintaining probiotics stability in food systems with various degrees of success. Delivery of probiotics through fermented foods such as fermented milks is a traditional practice. Mixed-culture fermentation is common in the food industry. In this presentation, enhancement of probiotics stability by mixed cultures of yeast and probiotics is discussed.

LEE YUAN KUNAssociate Professor, Department of Microbiology and Immunology National University of Singapore, SingaporeMicrobiome as Biomarker for Mental Health Status of Elderly and Target of TreatmentNumerous clinical and scientific evidences have demonstrated correlation between GI

microbiota and health and age of the host. Some elderly may gradually develop cognitive decline, which covers a large spectrum of clinical manifestations from normal ageing to mild cognitive impartment (MCI), a continuum that subsequently leads to dementia and related mental dysfunctions. Currently, elderlies are subjected to a series of diagnostic tests, such as the Mini Mental State Examination (MMSE) Test and the Montreal Cognitive Assessment (MoCA), in addition to extensive Neuropsychological Tests, to determine if they were showing signs of cognitive impairment. Other inputs from caregivers also contribute to the diagnosis, resulting in a labour-intensive and subjective workflow. These observations and scores are then assessed before a formal diagnosis of the patients’ mental and cognitive state is made. There have been many studies proposing the presence of a gut-brain axis, where the brain signals are believed to influence the gut functions, and that the gut microbiota will affect the neurosystem. Evidences of such gut-brain axis interaction have been reported, albeit with inconclusive involvement of specific bacterial types. The association of GI microflora with neurocognitive impairment disorder and dementia in elderly may serve as biomarkers for evaluation of cognitive health and status. It may open up novel approaches for maintenance of mental health.

CONGRESS SCHEDULE


11:30-11:55

11:30-11:55

LIU JIQUANPrincipal Scientist, Procter and Gamble, SingaporeThe Effect of Skin Cleansing Products on Skin Microbiota for Children with Atopic DermatitisAtopic dermatitis (AD) is the most common

cutaneous disease in children and features recurrent lesions and compromised barrier function. Good skin care practices, i.e. regular moisturiser application and proper bathing are recommended by medical community as an essential part of adjuvant therapy to AD disease. To evaluate the efficacy of skin cleansing technologies, including two ultra-mild moisturizing body wash products and a synthetic bar control, a randomised double-blind clinical trial was conducted in Beijing Children’s Hospital and Capital Institute of Paediatrics. The protocol consisted of 1-week pre-washout and 4-week treatment (the combination of 0.1% hydrocortisone butyrate cream and skin cleansing products). The corticosteroid cream treatment was available ad lib to all subjects because of the nature of the study and its consumption was monitored. After 4-week treatment, all treatment legs showed significant improvement in SCORAD from initial baseline conditions. However, the patients using the ultra-mild moisturising body wash products had significantly lower usage of corticosteroid (ca. 50% reduction) vs. those using the synthetic bar soap control. More importantly, the most advanced ultra-mild moisturising body wash technology containing both emollients and an antibacterial agent delivered significant benefits to the skin microbiota as shown in the Microbial index of Skin Health (MiSH Index), which was constructed by comparing the skin microbiota of AD and healthy subjects. It is also observed that the most advanced body wash technology provided

11:30-11:55

HSIN-CHIH LAIDirector, Microbiota Research Center and Department of Medical Biotechnology and Laboratory Science, Chang Gung University, TaiwanThe gut bacterium Parabacteroides goldsteinii

mediates the anti-obesity effects of mushroom polysaccharidesNovel anti-obesity measures that are safe, effective and widely available are needed to combat the growing obesity epidemic. In the present study, we show that a water extract of the medicinal mushroom Hirsutella sinensis reduces obesity, inflammation and insulin resistance in high-fat diet (HFD)-fed mice. A high molecular weight polysaccharide fraction (>300 kDa) isolated from the water extract not only lowers body weight by 50 to 70% but it also reduces intestinal permeability, metabolic endotoxemia, inflammation and insulin resistance. Horizontal fecal transfer combined with antibiotic-induced depletion of specific gut bacteria shows that the effects of H. sinensis polysaccharides are dependent on neomycin-sensitive bacteria. Gut microbiota analysis reveals that the Gram-negative bacterium Parabacteroides goldsteinii is highly reduced in the microbiota of HFD-fed mice, while this bacterium is enriched in polysaccharide-treated mice. Notably, oral administration of live, but not heat-killed, P. goldsteinii bacteria to HFD-fed mice considerably reduces weight gain and obesity-associated metabolic disorders. These results indicate that the anti-obesity, anti-inflammatory and insulin-sensitizing effects of mushroom polysaccharides are mediated by the gut microbiota and involve the newly identified probiotic P. goldsteinii. Mushroom polysaccharides and P. goldsteinii may thus be used

DAY 1 MONDAY 5TH MARCH 2018

MICROBIOME IN HEALTH AND DISEASES MICROBIOME R&D PROBIOTICS

TRACK CHAIR: JASNA RAKONJACAssociate Professor, Institute of Fundamental Sciences, Massey University, New Zealand

TRACK CHAIR: ERIC HUANGChair Professor, National Central University, Taiwan and Professor, Department of Dermatology, University of California, San Diego; USA

TRACK CHAIR:

ENDANG S. RAHAYUChairman of Indonesian Society for Lactic Acid Bacteria (ISLAB) and Professor, Faculty of Agriculture Technology, Gadjah Mada University, IndonesiaIndonesian Gut Microbiota and the Implementation of Local Probiotics

Gut microbiota is influenced by various factors, such as, early colonization, age, health, consumption of antibiotics, host genetics, physical activities, general life style, and the most important is diet habit including the consumption of probiotics. Gut microbiota reflects diet habit on a geographical area. Nakayama et al., (2015), reported that Indonesian children have a Prevotella (P)-enterotype just like Thai children from the urban area, and this reflects the high consumption of carbohydrates. On the other hand, the Taiwanese, Chinese and Japanese children have the Bifidobacterium/Bacteroides (BB) - enterotype, reflecting higher consumption on animal-based food. Both these enterotypes are strongly supported by different diets. Indonesia has a very wide area with various tribes, habit, and food pattern in accordance with the food availability of each region. So it is necessary to do research related to diet and gut microbiota in some areas with a specific diet. Research has been conducted to link the diet in several regions in Indonesia with gut microbiota and local probiotic consumption effect. Lactobacillus plantarum DAD-13 and L. plantarum Mut-3 isolated from local fermented food, are local probiotics which are being developed for pre-commercialization. The safety of these two bacteria have also been performed using Sprague Dawley rats that were force fed with a high dose of probiotic cells, furthermore, the ability of probiotic cells to translocate was determined, as

10:00-10:30

SPONSORED PRESENTATION:JANNEKE VAN DE WIJGERTProfessor of Infection and Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands, Institute of Infection and Global Health, University of Liverpool, UKVaginal probiotics to prevent vaginal dysbiosisMost women have a vaginal microbiota (VMB) that consists predominantly of lactobacilli, and vaginal dysbiosis (a VMB not dominated by lactobacilli) has been associated with increased risk of

HIV, pelvic inflammatory disease, miscarriage, preterm birth, and maternal and neonatal infections. Vaginal dysbiosis is typically only treated when symptomatic and the recurrence rate after standard metronidazole treatment is high. We recently conducted a randomised controlled trial of antibiotic and probiotic maintenance therapies with as aim to reduce recurrence rates in women at high risk of urogenital infections in Rwanda. After successful treatment, women (N=68) were randomised to Ecologic Femi+ (Winclove Probiotics, Netherlands, another vaginal probiotic, oral metronidazole, or behavioural counseling only. All interventions were self-administered 2-3 times per week for two months. My presentation will discuss the preliminary results of this trial and will place the results in the public health context.

Morning Refreshments / Poster Presentations / Scheduled One-to-One Meetings10:30-11:30

CONGRESS SCHEDULE



11:55-12:20

11:55-12:20

PATRICK LEE Associate Professor, School of Energy and Environment, City University of Hong Kong, Hong KongSeasonal Dynamics of the Bacterial and Fungal Skin Microbiomes of Chinese Individuals

The seasonal changes of the bacterial and fungal communities living on the skin of healthy Chinese individuals in Hong Kong were characterized in this study via high-throughput sequencing of the taxonomic markers. The bacterial and fungal communities exhibited different characteristics over time. Some of the skin community members were sourced from the environment and individuals who were co-inhabitants shared a more similar skin microbiome. Co-occurrence network analyses revealed potential interactions within the communities, and the roles of low abundance members in the communities were also considered. Overall, this study provided insights into how the skin microbiome varied over time and the results have implications for health of the hosts.

11:55-12:20

SAMANTHA COULSONAdjunct Assoc. Prof, The University of the Sunshine CoastFermented Foods: The Missing Food Group in the Australian Dietary GuidelinesFermented foods have been consumed for

thousands of years, in various forms and with many different cultural influences. These health-promoting foods are more prominently found in the diets of cultures that have adhered to their traditional dietary practices such as in Asia with kimchi, Kombucha and miso; Russia with kefir and Germany with sauerkraut. The predominant fermented foods typically eaten by the western population however are yoghurt, beer, wine and cheese and the only fermented food listed in the Australian dietary guidelines is yoghurt. This is not because of its beneficial effects due to the actual 'fermentation process' and the 'bacteria' but due to its calcium and protein content. Unfortunately most yoghurts contain unnecessary quantities of sugar and hence, unless chosen carefully, do not really represent a healthy choice of fermented foods. Scientific evaluation of the role of bacteria in health and disease has exploded in the last few decades, with research focusing on probiotic application for therapeutic effects. Research now however is also focusing on the significant health effects of fermented foods in particular kimchi, kombucha and kefir and their therapeutic application for treating metabolic and immune alterations seen in obesity, diabetes and cardiovascular disease among other conditions. This presentation will explain in-depth why fermented foods should be included as a critical food category within the Australian Dietary Guidelines to assist with reducing the chronic non-communicable (non-infectious) diseases that currently plague western societies.

HIROSHI OHNOGroup Director, Laboratory for Intestinal Ecosystem, RIKEN Centre for Integrative Medical Sciences (IMS), JapanSearch for Gut Microbial Biomarkers for Paediatric Atopic Dermatitis with A Birth Cohort

It has recently been reported that gut microbiota deeply impacts the pathogenesis of many diseases including allergies as a predominant environmental factor. However, the molecular mechanisms of how gut microbiota and/or its metabolites influence pathogenesis of allergies are not fully elucidated. To tackle this problem, we are analyzing a birth cohort, where 300 newborn babies are recruited and their feces are collected on a routine schedule (at 1 week, 1 month, and 1 year old). Fecal samples were subjected to16SrRNA gene amplicon sequencing as well as shotgun metagenomics sequencing, and the metabolomics were performed using GC-MS and LC-MS. 16S rRNA analysis revealed that individuals with increased Streptococcus species and Enterobacteriaceae family members at 1 week and 1 month, respectively, tend to suffer from atopic dermatitis (AD) at the age of 2 years. Metabolome analysis showed that short-chain fatty acids such as acetate and butyrate tended to be decreased in AD groups among the aqueous metabolites, consistent with previous studies. With lipid metabolome analysis, we found that hydroxy fatty acids were significantly decreased in faeces of AD group at 1 week old. Hydroxy fatty acids are known to possess anti-inflammatory effect, suggesting that decrease in these metabolites may contribute to AD pathogenesis.

12:20-12:50

SPONSORED PRESENTATION:DAVID KYLEChairman and CSO, Evolve BiosystemsFrom Dysbiosis to Recovery in the Infant Gut MicrobiomeOver 20 years of research at the University of California at Davis has established that the natural microbiome of the human infant is dominated by a single commensal species through its unique ability to consume Human

Milk Oligosaccharides (HMOs). Astonishingly, this natural microbiome has changed slowly, but extensively over the past 100 years due to the near extinction of this commensal species through the unintended consequences of extensive infant formula use, the multigenerational use of antibiotics, and recent increases in the C-section rate. We have now established that this new pandemic dysbiosis in gut of infants in developed nations can be remodeled back to the natural state through the reintroduction of this natural dominant commensal into the population along with breast-feeding or otherwise supplying HMOs to the infant. This new data sets the path forward to a major worldwide reestablishment of the natural infant microbiome over the next few years.

12:20-12:50

For sponsorship opportunities please contact [email protected]

Tel: +60 3 2117 5196 Cell: +60 1 6656 4828

SOLUTION PROVIDER PRESENTATION

11:30-11:55

11:30-11:55

a significant reduction of Staphylococcus relative abundance and significant increase in relative abundance of Propionibacterium, Corynebacterium and Streptococcus vs. synthetic bar soap control.

11:30-11:55

respectively as prebiotics and probiotics for the treatment of obesity and related metabolic complications.

well as epithelial cell condition. The results showed that Dad-13 and Mut-7 are safe for probiotic agents. Effect of probiotic strains consumption as a fermented milk drink, yoghurt or as supplement by healthy and obese volunteers were also studied, and their results will be discussed.

CONGRESS SCHEDULE



MICROBIOME IN HEALTH AND DISEASE MICROBIOTA AND SKIN CONDITION PROBIOTICS

13:50-14:15

13:50-14:15

THOMAS DAWSON JR.Senior Principal Investigator, Institute of Medical Biology, A*STAR, SingaporeFungi: Not just mushrooms, a functional target of your Skin MicrobiomeIn the current human microbiome research

landscape, there remain two related but underexplored knowledge gaps: skin and fungi. As there is recent increasing traction in these fields, the opportunity of leveraging the Skin Microbiome in therapeutic and commercial applications necessitates greater attention. This presentation will review two components: 1. The Asian Skin and Hair microbiome program (ASHM) in Singapore, with building capability in skin biology, big data and omics technologies in skin microbiology, and 2. Current understanding of healthy versus diseased scalp, the scalp Mycobiome, the role of Malassezia in dandruff and seborrheic dermatitis, state of the art in Malassezia genomics, and how current treatment options influence the scalp Mycobiome.

13:50-14:15

G. BALAKRISH NAIRAg Regional Advisor, Research Policy Cooperation Unit, Communicable Disease Department, World Health Organisation (WHO), IndiaMicrobiota Signatures of Under Nutrition in Resource Poor Settings

The onset and progression of undernutrition has been attributed to a variety of causal factors, which includes insufficient food, impaired immune responses, repeated enteric infections, dysregulated gut permeability all of which culminate in mal-absorption. The gut microbiota as a link between environmental factors such as diet and the host has received less attention. However recent studies involving a large cohort of twin pairs from Malawi, a resource poor country and also studies conducted in Bangladesh support a relationship between diet, gut microbiota and health and/or nutritional status and is also involved in severe acute malnutrition. A recent study conducted in a rural setting in West Bengal, India examined the metagenomes of 20 children with varying nutritional status. The Indian study describes patterns wherein the gut microbiome varies in response to nutritional status in a manner that nutritional deprivation leads towards “a disease promoting microbiota.” The biological basis of such changes and the mechanisms governing the occurrence of these patterns remain to be experimentally verified. Further studies are required to formulate a microbial basis of therapy for undernourished children.

14:15-14:40

14:15-14:40

MARIE DRAGOFounder, Gallinée, UKHow the microbiome is shaking the beauty industry• Understanding the role of the skin microbiome• What does it mean for existing players• 2018 trends and innovations 14:15-14:40

Invitation Out LIONG MIN TZEProfessor, Bioprocessing Technology,Universiti Sains Malaysia, MalaysiaProbiotics & Brain Health: The Gut-Brain-AxisProbiotics have a long history of safe use

and been documented for their various health benefits. They have been much emphasised on their roles to regulate gut well-being, including the alleviation of lactose intolerance, improvement of diarrhea and inhibition towards pathogenic bacteria in the gut. In the past decades, there is increasing evidence illustrating the benefits of probiotics that are beyond gut. The “gut-brain-axis” has suggested that probiotics play crucial roles in modulating brain health. This talk will highlight the applications of probiotics in these areas, with new mechanisms and evidence.

PRANAB KALITAGlobal Medical Director, GSK Consumer Health, SingaporeThe Gut-Brain -Axis Physiology & underpinnings

Lunch / Poster Presentations / Scheduled One-to-One Meetings12:50-13:50

CONGRESS SCHEDULE



MICROBIOME IN HEALTH AND DISEASE MICROBIOTA AND SKIN CONDITION PROBIOTICS

14:40-15:10

14:40-15:10


Tel: +60 3 2117 5196 Cell: +60 1 6656 4828


15:10-15:35

15:10-15:35

ERIC HUANGChair Professor, National Central University, Taiwan and Professor, Department of Dermatology, University of California, San Diego; USAEditing Skin Microbiome and A Skin Probiotic Bank

We have established a Skin Probiotic Bank by isolating fermenting bacteria from human skin. These fermenting bacteria can be used as probiotics for treatment of various skin diseases including acne vulgaris and atopic dermatitis. We have also synthesised several selective fermentation initiators (SFIs), which can amplify the fermentative activity of skin probiotic bacteria against pathogens. To recalibrate the dysbiotic skin microbiome, SFIs are used to exclusively trigger the fermentation of probiotic bacteria. This talk will describe how we use this Skin Probiotic Bank for Skin Microbiome Banking. Most importantly, this presentation will also summarise how these skin probiotic bacteria impact the future development of drugs, vaccines, probiotics/prebiotics and diagnostics for treatments of skin diseases.

15:10-15:35

JOY CHONGPrinciple Clinical Pharmacist, Watson’s Personal Care Stores, SingaporeGap in probiotic consumer marketIn recent years, there is a growing interest in probiotics use among consumers. As a frontline healthcare professional, community pharmacists receive and address numerous queries from concerned consumers who are confronted with a myriad of options available. In this session, Joy Chong, who is the principal clinical pharmacist at Watsons, will be sharing with you various insights into the probiotic market. With over a decade of experience in patient care, she will highlight the unmet needs of her customers as well as on the need for more research to be conducted to guide optimal usage of probiotic.

NIRANJAN NAGARAJANSenior Group Leader and Associate Director, Computational and Systems Biology, Genome Institute of Singapore (GIS), A*STAR, SingaporeImpact of antibiotic therapy on gut microbiome

Antibiotics are the wonder drugs of the 20th century with billions of doses being consumed every year around the world. Antibiotic usage is, however, a common cause of gut microbial dysbiosis in children and adults and has been associated with several metabolic and allergic diseases, including diabetes and atopic dermatitis. Antibiotic induced dysbiosis in the gut microbiome typically resolves itself within a few weeks but can persist for extended periods of time in some individuals (> 1 year), and thus increase the risk for colonisation by opportunistic, frequently multidrug resistant, pathogens. Despite its importance for host health, mechanisms for gut microbiome recovery post antibiotics remain unknown. Using longitudinal metagenomic analysis in >90 subjects taking antibiotics in 3 continents, we identified shared microbial biomarkers that associate with enhanced microbiome recovery. Further analysis of the ecological interactions in the gut microbiome suggests that many recovery associated bacteria (RABs) are primary colonising species that break down complex carbohydrates to support the growth of

14:40-15:10

SPONSORED PRESENTATION:CHARLOTTE TROISEAPAC Scientific Manager Lesaffre Human Care, SingaporeibSium®, a unique probiotic yeast for the management of abdominal pain: clinical

evidence in patients with Irritable Bowel SyndromeChronic abdominal pain is a very common gastrointestinal (GI) disorder affecting up to 20% of the population. However, because of the lack of long—term treatments satisfaction, both patients and caregivers turn to alternative methods such as probiotics. ibSium® (Saccharomyces cerevisiae CNCM I-3856) a unique probiotic yeast strain from Lesaffre, has demonstrated its beneficial properties in alleviating GI symptoms in two randomized placebo controlled clinical trials involving a total of 579 subjects suffering from Irritable Bowel Syndrome (IBS). These results were confirmed in a recent individual patient data meta-analysis. All together, these data support a promising role for ibSium® as an alternative for clinician looking for new opportunities of natural treatments on a long term perspective.

SPONSORED PRESENTATION:TAKASHI OHDANDirector of R&D, Genesis Healthcare Co., Japan

MAMIKO ISAJISenior Scientist, Genesis Healthcare Co., JapanTitle TBC

CONGRESS SCHEDULE




16:35-17:00

16:35-17:00

JI GEUN EOGProfessor, Department of Food and Nutrition, Research Institute of Human Ecology, Seoul National University, KoreaDevelopment of Evidence-based Probiotic Strains and Bifidogenic PrebioticsImprovement of intestinal microflora comprise a main function of intestine-related healthy functional foods. Various human-originated probiotic strains including

Bifidobacterium bifidum BGN4, B. longum BORI, Lactobacillus paracasei CH88 were developed through the series of in vitro and animal experiments. In three separate double-blind, randomized placebo-controlled human trials the products containing combinatory probiotic strains containing B. bifidum BGN4 significantly lowered the prevalence of atopic dermatitis in infants and also significantly lowered the pain scores and increased the bowel movement comfortability in irritable bowel syndrome patients. Global metabolomic analysis showed that anti-inflammatory biomarkers were enhanced in the probiotics group. When infants and toddlers hospitalized with rotavirus infection were treated with probiotic products containing B. longum BORI the symptoms such as duration of fever, frequency of diarrhea, and frequency of vomiting were ameliorated better by the probiotics than the placebo. The full genome sequences of the developed probiotic strains were determined and assessed on their safety and functionality aspects. Moreover, various novel oligosaccharides including fucosyl-galactose were developed.

17:00-17:25

16:35-17:00

SEBNEM HARSAProfessor, Department of Food Engineering, Izmir Institute of Technology, TurkeyDeveloping a Guide of Bioinformatic Database for Probiotic ProductsBioinformatics is generally defined as collecting and analysis biological data. Establishing a bioinformatic system for probiotics, would have a potential to emphasize the beneficial impacts for human health, while having an ability to cross examine on

diseases and products. The main objective of this study is to develop a new comprehensive guide that includes; in vitro, in vivo and clinical research data on probiotics to be used by pharmacists, hospitals and pharmaceutical industry; also for well being purposes by consumers. Besides, goals of this study include dissemination of knowledge for consumer awareness together with collection of scientific evidence based on probiotic products. Within this context, such a database may rapidly provide answers, such as, which probiotic product could be used for which illness in specific. Consequently, any successful applications of bioinformatics in the area of probiotics especially for pharmaceutical industry, is needed to indicate a gateaway, forming a transition from preliminary to in-silico studies.

WON WOO CHOIExecutive Advisor, Genome and Company, KoreaDiscovery of New Cosmetic Ingredients from Human Skin Preventing Aggravation of Atopic Dermatitis or Inflammation of Acne Several related studies have shown that the alteration of skin microbial population associated with various skin diseases. Acne, atopic dermatitis and psoriasis are

well-known skin diseases about the alteration of skin microbial population. But the shift of skin microbial communities in the pathogenesis of atopic dermatitis or acne is not clearly understood. We have focused on research to reveal the pathogenic mechanism of alteration of skin microbial population in acne and atopic dermatitis and provide a new microbial approach to improve atopic dermatitis and acne.

Afternoon Refreshments / Poster Presentations / Scheduled One-to-One Meetings15:35-16:35

15:10-15:35

15:10-15:35

Continued

15:10-15:35

other bacteria. Preliminary experiments in a mouse model of antibiotic induced dysbiosis recapitulate the ability of RABs to promote enhanced microbiome recovery, and potentially provide colonisation resistance against opportunistic pathogens. These results suggest that there is potential to rationally perturb the gut microbiome for promoting recovery and improving host health after antibiotic treatment.

Continued

JASNA RAKONJACAssociate Professor, Institute of Fundamental Sciences, Massey University, New ZealandMolecular Gold in Microbial Genomes and Metagenomes Using Phage Display Technology Microbes are engaged in complex interactions with the environment, host, and with other members of microbial community. Identification of molecular factors

that mediate or modify those interactions is essential for understanding and ultimately manipulating the effect of a microbe or microbial community on the host. By screening phage display libraries derived from individual bacteria or archaea, or from microbial communities, we have identified novel surface proteins, including adhesins, some of which mediate broad inter-kingdom interactions. We demonstrate that phage display technology, combined with the recent advances in DNA sequencing technologies, provides a powerful approach for cultivation-independent discovery of molecular basis for a range of ecologically and medically important microbial interactions.

Drinks Reception and End of Day 117:25

CONGRESS SCHEDULE DAY 2 TUESDAY 6TH MARCH 2018

08:50-09:15

KEYNOTE ADDRESS:TODD KRUEGERPresident and CEO, AOBiome Therapeutics, USAThe Role of Ammonia Oxidizing Bacteria in Human HealthAmmonia Oxidizing Bacteria are an important evolutionary component of human evolution. Modern living has separated us from the source of these critical

bacteria and modern chemistry has removed them from our microbiomes. The removal of AOB’s has led to a disruption in the nitrogen cycle. Restoring the nitrogen cycle has shown preliminary benefit across a number of inflammatory conditions ranging from skin disease, hypertension to migraines. AOBiome is developing a first-in-class live biotherapeutic solution to address these modern conditions.

08:00-08:50

Morning Chair: John Common, Principal Investigator, Institute of Medical Biology, A*STAR, Singapore


08:50-09:15

KEYNOTE ADDRESS:LIONEL BRETONScientific Director Advanced Research, L’Oreal R&I , Biotherm Advisor, France Vitreoscilla filiformis, a spa spring water bacterial strain used since centuries as an original translation of probiotics’ benefits to skincareAtopic xerosis and dandruff are both sub-inflammatory skin disorders driven by immune

dysfunctions and are characterized from early stages by itch and delay in healing. As recently described, these two disorders are associated with specific dysbiosis of the skin microbiome with altered microbial diversity characterized by excess of Staphylococcus spp. or Malassezia spp., respectively. In skin aging as a subclinical condition, a dysbiosis was also recently described with an overabundance of oral bacterial strains usually not present on the skin together with a decrease of a commensal strain (Propionibacterium acnes). These dysbiosis and associated clinical signs may be controlled by Toll Like Receptor (TLR) specific ligands. The notion of dermatological thermal water-based treatments is dating back to Ancient Greece and the Roman Empire. In 1950, French scientists created a new skincare product using a mineral water from the thermal springs of Molitg-les-Bains in the Pyrenees mountains. They explained the skin rejuvenating and protecting activities of this product by the presence of a living specific non-pathogenic filamentous bacterial strain unique to these springs: Vitreoscilla filiformis. Clinical studies published in many journals of dermatology validated that this harmless bacteria could improve skin health and confer benefits similar to probiotics for gut health. The action mechanism of Vitresocilla filiformis strain has recently been understood: it contains TLR subtype 2 ligands (probably counteracting Microbial Associated Molecular Patterns (MAMPs) of sub-pathogenic strains, in case of dysbiosis) which regulate the skin barrier function and skin innate defenses through microbiome balance. As also known from probiotics, TLR2 signaling induces tolerogenic interleukin-10 which may explain the clinical effects of Vitreoscilla filiformis. In addition, the ability of this strain to induce defensins (def 2-4) may contribute to maintain healthy skin conditions.

Refreshments

Morning Chair: Lim Yin Sze, Assistant Professor and Course Coordinator (Nutrition), School of Biosciences, Faculty of Science, Nottingham University, Malaysia

09:15-09:40

09:15-09:40

SOMYING TUMWASORNAssociate Professor and Head Division of Bacteriology, Faculty of Medicine, Chulalongkorn University, ThailandLeaky Gut- Associated Diseases and ProbioticsThe intestinal epithelium provides a physical barrier to intestinal microbiota, pathogens and toxic luminal contents, and thus prevents infection and

inflammation. This barrier function is regulated in part by tight junctions (TJs) which seal the paracellular space between epithelial cells. Different factors such as stress, pathogens, inflammatory cytokines and high-fat diets can affect the integrity of TJs resulting in the leak of epithelial barrier known as “leaky gut”. Disruption of the integrity and function of the intestinal epithelium plays a crucial role in the pathogenesis of numerous diseases such as infectious diseases, inflammatory diseases and metabolic diseases. This talk will provide the information of in vitro and animal studies of Lactobacillus rhamnosus L34 for the prevention of leaky gut in Clostridium difficile infection and gut translocation-induced bacterial sepsis, and address its potential as a probiotic for other associated diseases.


ANINDYA DASGUPTAWorkstream Leader - Genesis Program, Unilever R&D, IndiaA Facewash Containing Specific Plant Derived Monoterpenes Reduces Propionibacterium Aches Burden and Improves Ache SymptomsThe pathogenesis of acne is multifactorial, including increased sebum production, ductal epidermal proliferation, bacterial colonization and inflammation. While the

sequence of events involved in acne pathogenesis have not yet been established, there is a strong co-relationship between the presence of acne and growth of the microorganism Propionibacterium acnes (P acnes) leading to suggestions that P. acnes is one of the major causes of acne. Recent studies have also shown an increased level of Staphylococcus epidermidis (S epidermidis) co-relating with acne. As reported separately, we have shown through in-vitro assays that the plant derived monoterpenes of thymol and terpineol act synergistically against a variety of bacteria, including P acnes . To better understand the impact of these plant-derived monoterpenes on the acne microbiome a 4 week clinical study was conducted. The clinical study was done as a double blinded, placebo controlled design with a population of approximately 30 acne volunteers with a face wash containing thymol and terpineol to use twice daily for the four week period while the healthy control volunteers were given a mild face cleanser. A reduction of nearly 20% acne lesions was observed in volunteers using the facewash with thymol and terpineol compared to control. Using a q-PCR based assay, we determined the abundance of P acnes and S epidermidis on face both initially and after 4 weeks of product use. We observed a

CONGRESS SCHEDULE

11:40-12:05

11:40-12:05

PHIL HANSBROProfessor, NHMRC Fellow and Brawn Fellow, School of Biomedical Sciences and Pharmacy, Newcastle University, AustraliaModifying Gut Microbiota to Treat Asthma and COPD

Respiratory diseases are major clinical issues. Ten-12% of Australians have asthma and chronic obstructive pulmonary disease (COPD) is the third commonest cause of death in the world. There are no effective treatments for severe asthma or COPD. Asthma results from aberrant T cell responses to innocuous antigens and in Western countries cigarette smoking is the commonest cause of COPD. In both diseases chronic inflammation results in tissue damage leading to airway remodeling, mucus hypersecretion and fibrosis that combine

11:40-12:05

GORDON HOWARTHProfessor, Gastrointestinal Physiology, School of Animal and Veterinary Sciences, University of Adelaide, AustraliaClinical Utility of Probiotic-Derived FactorsThere is accumulating evidence that factors

derived from culture supernatants of certain probiotic bacteria may have clinical applications for a range of gastrointestinal disorders affecting humans and animals; negating the need to administer living organisms. These disorders include chemotherapy-induced mucositis, the inflammatory bowel diseases ulcerative colitis and Crohn’s disease, and neoplasms such as colorectal cancer. As an example, in the pre-clinical setting, Escherichia coli Nissle 1917 and Faecalibacterium prausnitzii have been demonstrated to generate cell-free

MIKE TAYLORAssociate Professor, Biology Sciences, Faculty of Science, University of Auckland, New ZealandDiet induces OTU-specific responses in a clinical trial of type 2 diabetes

The gut microbiota has been linked to type 2 diabetes (T2D) in a number of studies, yet the exact nature of the association remains unclear. This is partly due to the confounding factors of diet and disease pathology. We analysed the microbiota from two human cohorts, comprising individuals with or without T2D (n=10 for each), who were placed on a strictly controlled, energy and nutrient balanced diet in a residential metabolic facility for 13 days. All faeces produced during the 13-day period were collected and the faecal microbiota analysed using

DAY 2 TUESDAY 6TH MARCH 2018


PREBIOTICS AND DIET R&D OUTSIDE THE GUT PROBIOTICS CONGRESS

Track Chair: Yunn Hwen Gan, Associate Professor, Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore (NUS), SingaporeNottingham University, Malaysia

Track Chair: John Common, Principal Investigator, Institute of Medical Biology, A*STAR, Singapore

Track Chair: Lim Yin Sze, Assistant Professor and Course Coordinator (Nutrition), School of Biosciences, Faculty of Science, Nottingham University, Malaysia

10:10-10:40

PANEL DISCUSSION:A Step to Commercialisation: Building A Microbiome Network Between Academics and Industry for Microbiome Discovery Efforts

PHIL HANSBROProfessor, NHMRC Fellow and Brawn Fellow, School of Biomedical Sciences and Pharmacy, Newcastle University, Australia

THOMAS DAWSONSenior Principal Investigator, Institute of Medical Biology, A*STAR, Singapore

10:10-10:40

PANEL DISCUSSION:Towards Prevention and Cure: Exploring the Status of Future Research and Policy on Probiotics Use in Asia

NEERJA HAJELAGeneral Manager, Science and Regulatory Affairs, Yakult Danone India

LIONEL BRETONScientific Director Advanced Research, L’Oreal R&I , Biotherm Advisor, France

Morning Refreshments / Poster Presentations / Scheduled One-to-One Meetings10:40-11:40

09:40-10:10


Tel: +60 3 2117 5196 Cell: +60 1 6656 4828

SOLUTION PROVIDER PRESENTATION09:40-10:10


Tel: +60 3 2117 5196 Cell: +60 1 6656 4828


09:15-09:40

09:15-09:40

Continued

change in microbial ecology with a significant increase in the abundance of P acnes and S epidermidis in acne subjects compared to the subjects who did not have acne. These results show that the plant derived monoterpenes of thymol and terpineol can normalize the level of P acnes and S epidermidis in individuals with acne to a state that is close to health, leading to a reduction in acne symptom.



12:05-12:30

12:05-12:30

12:05-12:30

JUN KUNISAWAHead, Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), JapanInvolvement of Diets and Commensal

Bacteria in the Regulation of Lipid-mediated Immune Regulation for the Control of Health and DiseasesDiets provide fundamental components for the establishment of body and simultaneously affect the composition and function of gut commensal bacteria, another key factor in the regulation of various host biological responses. Reciprocally, gut commensal bacteria is involved in the digestion of diets to consequently produce either useful or harmful metabolites. We have studied the immunologic influence of fatty acid composition in dietary oils on the regulation of host immune responses. In a previous study, we showed that fatty acid compositions in the dietary oils affect the development of allergic and inflammatory diseases together with identification of anti-allergic lipid metabolites by metabolome analysis. Although large numbers of study focused on the lipid metabolites generated in the body, our studies demonstrated that commensal bacteria is also involved in the generation of lipid metabolites from dietary oils in the intestinal lumen. In this talk, I describe recent findings regarding the immunologic crosstalk between commensal bacteria and dietary oils in the regulation of host immunity including the development of allergic and inflammatory diseases and application to the development of anti-allergic and anti-inflammatory functional foods and drugs.

11:40-12:05

11:40-12:05

to impair lung function. Alveolar destruction and emphysema also occur in COPD. Current therapies are ineffective alleviating some symptoms but do not reverse nor cure the disease. The microbiome encompasses all the microorganisms that inhabit the body. Recent studies show that a healthy microbiome is essential for maintaining homeostasis and health. Changes in the airway and lung microbiome may contribute to the pathogenesis of asthma and COPD. Deleterious bacteria may promote whereas beneficial bacteria may suppress inflammation and disease. These may be altered by immune responses to allergens and cigarette smoke. Alterations in the gut are associated with colitis, which may also ne mediated by changes in the microbiome. Substantial immune and inflammatory cross-talk occurs between the lung and gut, and so changing gut microbiomes may be beneficial for lung disease. Microbiome profiling can be used to assess the changes that are associated with disease. Transfer of microbiomes, eg by faecal transfers, can modify microbiomes. This can identify deleterious and beneficial bacteria and be of potential therapeutic benefit.

11:40-12:05

supernatants with therapeutic efficacy against intestinal mucositis. This presentation will describe the current status of probiotic-derived factors and their potential to contribute to digestive disorder management.

SARAH PRIOURResearch Associate, Massey Institute of Food Science and Technology, New ZealandProbiotic encapsulation and protectionIn the most recent research gut health has been highlighted as key to overall optimal

health. The delivery of probiotics, in both food applications and tablet form, is seen as a valid route to improve gut microflora. However, these cells are highly susceptible to multiple stresses which are encountered when adding them to foods such as high processing temperatures, drying, long storage times, water activity and high salt/ sugar concentrations. This has resulted in extensive research into the encapsulation of probiotics, with the hope of protecting them from adverse environmental conditions. This talk will explore in greater depth the most promising methods and materials that have been found to date for protecting probiotics and what still needs to be done before we can deliver these cells in a viable state in a range of applications.

bacterial 16S rRNA gene amplicon sequencing. While the overall microbiota profile was similar, and did not change substantially during the trial, for the two cohorts, specific bacterial OTUs underwent markedly different abundance trajectories in diabetic vs healthy participants. For example, an OTU affiliated with Bifidobacterium adolescentis was initially 6x more abundant in the T2D cohort, but within five days converged to identical abundance in the two cohorts. By contrast, the abundance of a Coprococcus OTU diverged significantly between the T2D and healthy cohorts over the course of the trial. These discordant responses of specific OTUs highlight the need to look at species- or strain-level differences rather than wholesale changes across the entire microbiota.

DEV MITTARLead Scientist, ATCC, USAATCC® Microbiome Standards: A Comprehensive Solution for Microbiome Assay Development and StandardizationAdvancement and accessibility of next-

generation sequencing technologies have influenced microbiome analyses in tremendous ways, opening up applications in the areas of clinical, diagnostic, therapeutic, industrial, and environmental research. A shortcoming in microbiome analyses is the lack of reference standards to control biases introduced by differential DNA extractability, sequencing methods, and data analysis. One of the primary obstacles in assay standardization is the limited availability of reference materials. To address this, ATCC has developed microbiome reference standards (set of mock microbial communities) from fully sequenced and characterized ATCC strains that were selected on the basis of phenotypic and genotypic attributes or their availability in clinical or natural environments. To further enhance the use of microbiome reference standards and eliminate the bias associated with data analysis, we have also developed a data analysis module in collaboration with One Codex that provides simple output in the form of true-positive, relative abundance, and false-negative scores for 16S rRNA community profiling and shotgun metagenomic sequencing.



12:30-13:00

12:30-13:00


Tel: +60 3 2117 5196 Cell: +60 1 6656 4828

COMPANY SHOWCASE PRESENTATION

12:30-13:00

COMPANY SHOWCASE PRESENTATION:SENIOR REPRESENTATIVEL'OrealTitle TBC

COMPANY SHOWCASE PRESENTATION:CAROLINE MONTELIUSAssociate Scientist, Probi AB, SwedenBeyond Gastro-indications – Can probiotics act in iron absorption, osteoporosis, gluten

intolerance and in enhancement of the immune system?It all started with a mission to save lives. Back in 1980ies, Gastroenterologists at Lund University Hospital, Sweden, started a collaboration with Microbiologists at Lund University, aiming at understanding why patients at the ICU unit suffered from sepsis and died, despite intensive antibiotics treatment. They discovered that healthy individuals, and those severely ill patients, showed large differences in the gut microbiota composition. By isolating one of the most frequent bacteria in healthy individuals and giving that strain to the patients in the ICU, they could prevent sepsis and death. By these steps one of the worlds most researched probiotic strains, Probi’s patented Lactobacillus plantarum 299v, was identified. For many years, and still today, the main focus for probiotics is gastrointestinal health. However, in the scientific community there are many other areas where probiotics have shown to have great impact. Probi, a research-dedicated company, with offices both in Sweden, the US and Singapore, continuously strive to perform several state-of the-art clinical trials every year. In 2018 alone, we will finish eight clinical trials, in several different health indications. The presentation will focus on the studies and recent data in three new indications - iron absorption, osteoporosis and gluten intolerance, as well as present key results from Probi’s latest, and largest ever, clinical study within the immune area, including 900 subjects over three seasons.

13:00-13:25

13:00-13:25

13:00-13:25

CLAUS CHRISTOPHERSENSenior Research Fellow – Human Microbiome Collaboration Centre, Curtin University and Edith Cowan University, AustraliaGut Health consequences of a long-term Palaeolithic diet compared to following the Australia Guidelines for Healthy Eating

To compare the long term (>1yr) health impacts of the Paleolithic diet in a cross sectional, case-control study. 51 self-reported long-term followers of the Paleolithic diet (≥1 year) was recruited and age and sex matched with 51 participants following the Australian Guide to Healthy Eating (AGHE) (total n=102). Once inclusion criteria were met and consent provided, participants completed a diet history interview, 3-day weighed food record and provide a 48-hour stool and 24-hour urine collection and fasting blood sample. Primary outcome measures

YOSHIHISA YAMASHITAProfessor and Chairperson, Section of Preventive and Public Health Dentistry, Kyushu University, JapanOral Microbiome Related to Pneumonia Mortality in Nursing Home Residents

This study investigates the relationship between tongue microbiota composition and incidence of pneumonia-related deaths, in nursing home residents (n = 173). Tongue microbiota profiles were classified into two community types: type I was dominated by Prevotella and Veillonella species, while type II was dominated by Neisseria and Fusobacterium species. All subjects were followed prospectively for a median of 19 months to assess the incidence of all-cause death, including pneumonia-related death and risk estimates of microbiota effects on death were estimated using multivariate Cox

HAZREEN ABDUL MAJIDAssociate Professor, Department of Social and Preventive Medicine, University Malaysia, MalaysiaImpact of Probiotics Supplementation Towards Respiratory Tract Infections Among Female Rugby Players

Prolonged exercise has been associated with altering the immune function and thus increasing the risk of acquiring an infection. Acute upper respiratory tract infection (URTI) is one of the most common medical condition affecting athletes. Probiotics is an emerging nutrition supplement that is actively been investigated to see its impact towards immune function and reduce the risk of some infections. Most studies were conducted in temperate climate. The aim of this study was to examine the effect of daily supplementation with multi-strain probiotics (Hexbio) for 8 weeks



Lunch / Poster Presentations / Scheduled One-to-One Meetings13:25-14:25

13:00-13:25

13:00-13:25

13:00-13:25

included; stool microbiota analysis, faecal biochemistry (SCFA, ammonia, secondary bile acids, cresols), serum SCFA, BCAA, TMAO, fasting glucose and lipids (total cholesterol, LDL, HDL and triglycerides). The primary aim of this experiment was to determine if a long term Paleolithic diet adversely effects gut health and markers of cardiovascular and metabolic disease.

proportional hazards regression analysis. The subjects with type I microbiota exhibited a significantly greater risk of all-cause death (adjusted hazard ratio [aHR] = 3.79, 95% confidence interval [CI] = 1.38-10.39) and pneumonia-related death (aHR = 13.88, 95% CI = 1.64-117.21), than those with type II microbiota, but there was no significant association between microbiota type and other-cause death. In conclusion, the tongue microbiota type is significantly associated with an increased mortality risk from pneumonia in nursing home residents.

on respiratory tract illness among female rugby players. This study was a randomised double blind placebo-controlled trial to examine the effects of probiotics supplementation on incidence and severity of URTI and physical performance among athletes in Kuala Lumpur. Of the thirty participants recruited, twenty-four participants (12 PRO, 12 PLA) completed the full eight weeks of the study. Participants recorded symptoms of URTI using Self-Reported Daily Illness Log developed by a sports institute. Current finding suggested daily supplementation with probiotics did not result in reduced incidence of URTI or the number of days of URTI symptoms among athletes. The differences in blood leukocytes and inflammatory markers at pre- and post- supplementation were not significant (p>0.05) in probiotics supplemented group. In conclusion, current preliminary study showed regular ingestion of multi-strain probiotics does not show to reduce the incidence, duration and severity of URTI in athletes. Further study is important to evaluate the effectiveness of this supplement over longer period of time and different sports.

JIAN-YONG WUAssociate Professor, Department of Applied Biology, Hong Kong Polytechnic University, Hong KongPrebiotic Functions of Polysaccharides from Edible and Medicinal FungiEdible fungi or mushrooms provide a rich source of polysaccharides with various bioactivities and health benefits such as antitumour, immunomodulation and

antiinflammation. The polysaccharides from mushrooms have diverse structures such as chitin, β- and α-glucans, mannans, xylans, and galactans and many heteropolysaccharides. Many of the fungal polysaccharides are non-digestible in the upper gut of human gastrointestinal tract and can only be utilized as dietary fibres by the gut bacteria in the large intestine. Therefore, the health benefits of fungal polysaccharides may be associated with their prebiotic function on the gut microbiota. Recently mushrooms have been recognised as a potential source of prebiotics, and a number of studies have explored the prebiotic functions of polysaccharides from some important edible or medicinal mushrooms such as Lentinus edodes (Shiitake), Trametes versicolor (Yunzhi), and Ganoderma lucidum (Reishi). This lecture will give a brief review on the prebiotic effects of fungal polysaccharides and their molecular characteristics. More details will be shown of our recent studies on the prebiotic functions of exopolysaccharides (EPS) produced by a medicinal fungus, Cordyceps sinensis fungus Cs-HK1. The EPS isolated from the Cs-HK1 fermentation broth had a high molecular weight (MW) and was partially degraded with high-intensity ultrasound, and further with acid. The acid-degraded EPS fraction with the lowest MW was useful for the growth and short chain fatty acid production of Bifidobacteria in culture, while the high MW EPS showed strong protective effects on the viability and survival bifidobacteria over long period of storage and in harsh conditions.

PREBIOTICS AND DIET PROBIOTICS IN ANIMAL AND AQUACULTURE

14:25-14:50

14:25-14:50

SORNTHEP TUMWASORNProfessor, Animal Science and Chairman of Advisory Board, Department of Animal Science, Kassetsart University, ThailandInnovative Research and Commercial Application of Prebiotics, Probiotics, Postbiotics, and Synbiotics in Livestock in ThailandThe use of antibiotics as growth promoter in livestock is almost nearly completely

banned now and alternative feed additives are needed. In this study the innovative research on the use of prebiotics, probiotics, postbiotics and synbiotics was reported focusing on pigs, beef cattle, dairy cows, and broilers. Our use of a postbiotic was first developed in livestock in 2007, followed by other studies on prebiotics, probiotics and synbiotics. The use of vinasses as a postbiotic in fattening pigs in a commercial farm was reported to significantly increase the average daily gain and reduce production cost. Pigs and fattening cattle fed with the mixture of vinasses and agricultural by-products had a significant increase in performance and lower mortality rate. Cows fed vinasses in the total mixed ration exhibited less methane and yielded more milk and favorable fatty acid composition. SuperYea, our innovative product containing both prebiotics and postbiotics, was applied to the production of farm animals. Our study showed that SuperYea supplement improved milk quality in dairy cows, enhanced the immune response and improved carcass quality in pigs, but yielded non-significant higher growth performance in broilers. The application of three types of probiotics either alone or in combination with SuperYea (synbiotics) or SuperYea alone (prebiotics and postbiotics) was investigated in pigs. Pigs fed SuperYea had higher performance than those receiving a single strain probiotic. However, the use of a synbiotic (SuperYea + Lactobacillus lactis) was found to significantly improve feed conversion ratio from weaning to 100 kg. The commercial application of SuperYea in livestock production in Thailand in the past 5 years has been successful. The continuous research and development on synbiotic effect from candidate probiotics mixed with SuperYea is important to fulfill the growing need for more efficient livestock production.


14:50-15:15

14:50-15:15

ANDERS CERVINProfessor, University of Queensland Centre for Clinical Research, Australia, Royal Brisbane & Women’s HospitalTopical probiotics in airway diseaseDiscovery of a microbial residential flora in the nasal cavity, sinuses and lungs have changed the way we see airway pathophysiology and has opened up new

therapeutic alternatives including bacteria-therapy and phage-therapy. Most studies of the airway have explored the role of systemic probiotic intervention using the so-called gut-lung axis to modulate pathophysiological events taking place within the mucosal epithelium of the airway. In my presentation, I will discuss studies that demonstrate a direct effect on the target area through nasal administration or oral sprays, with a special interest in tonsillitis, otitis media and chronic sinusitis. In this overview, I will further discuss the obstacles we are facing and present a strategy for future probiotic research in airway disease with an emphasis on topical treatment.

NICK GORGANICEO, OzStar Therapeutics, AustraliaImproving Clinical Outcomes in Type 2 Diabetes Patients on Sulfonylurea DrugsType 2 diabetes mellitus (T2DM) patients are prescribed with a number of oral and injectable medications, each of which has significant side effects. Whilst side effects such as hypoglycemia, weight gain and gastro-intestinal tolerability are

associated with older anti-diabetes agents, the newly marketed drugs are associated with tolerability and safety issues including increased risk of infections, pancreatitis, bone fractures, fluid retention, amputation and congestive heart failure. The currently marketed anti-diabetes drugs generally have limited efficacy, necessitating multiple drugs to control most patient’s glycaemia. Consequently, due to intake of multiple drugs, each having their own side effects, as well as the progressive nature of the disease, T2DM patients may experience a multitude of side effects. Thus, T2DM remains a challenge and there is a need for better, safer and ideally cheaper treatments.

Close of Conference15:15

POSTER PRESENTATIONS

MAKING A POSTER PRESENTATION

Poster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters. We also issue a poster eBook to all attendees with your full abstract in and can share your poster as a PDF after the meeting if you desire (optional). Whether looking for funding,employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.

In order to present a poster at the congress you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). We charge an admin fee of $50 to industry delegates to present, that goes towards the shared cost of providing the poster presentation area and display boards, guides etc. This fee iswaived for those representing academic institutions and not for profit organisations.

VENUE INFORMATION

Hotel Fort Canning,11 Canning Walk, Singapore, 178881www.hfcsingapore.com

Hotel Fort Canning is a magnificent and award-winning conservation hotel tucked within 18 hectares of lush greenery of Fort Canning Park. The award-wining boutique hotel is luxurious and trendy,and it combines the romance of a grand colonial edifice with lush green parklands in the heart of the city. Hotel Fort Canning was styled by the award-winning DP Architects to incorporate the finest hospitality amenities,while retaining and conserving its old-style, colonial glamour. Today, the hotel serves as one of the finest boutique hotels Singapore has to offer. It straddles the Orchard Road shopping belt, the Clarke Quay entertainment hub, the Central Business District and the Civic District.


Documents

4 MICROBIOME R&D BUSINESS COLLABORATION CONGRESS · Yakult Danone India ... • Feed additives to target disease ... • Examining the probiotic market in the Asia-Pacific region